Cargando…
Prognosis and treatment differences between initial and second primary chondrosarcoma
Prognosis and treatment differences between initial and second primary chondrosarcoma (pCS) remain unknown. In the present study, patients with chondrosarcoma diagnosed between January 2004 and December 2015 were identified using the Surveillance Epidemiology and End Results database. Kaplan-Meier c...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6539928/ https://www.ncbi.nlm.nih.gov/pubmed/31289490 http://dx.doi.org/10.3892/ol.2019.10329 |
_version_ | 1783422505242853376 |
---|---|
author | Mao, Weipu Kong, Minghao Yu, Haiyang Wang, Dongyan Huang, Xin Yao, Xudong Fan, Jie Geng, Jiang |
author_facet | Mao, Weipu Kong, Minghao Yu, Haiyang Wang, Dongyan Huang, Xin Yao, Xudong Fan, Jie Geng, Jiang |
author_sort | Mao, Weipu |
collection | PubMed |
description | Prognosis and treatment differences between initial and second primary chondrosarcoma (pCS) remain unknown. In the present study, patients with chondrosarcoma diagnosed between January 2004 and December 2015 were identified using the Surveillance Epidemiology and End Results database. Kaplan-Meier curves and log-rank tests were used to assess overall survival (OS) and cancer-specific survival. Univariable and multivariable Cox regression analyses were used to determine factors associated with all-cause mortality and cancer-specific mortality. In total, 1,655 eligible patients were included in the cohort of the present study, of which, 1,455 (87.9%) had initial pCS and 200 (12.1%) had second pCS. Patients with second pCS were more frequently diagnosed in the age range of 61–80 years compared with patients with initial pCS (52.5 vs. 43.1%; P<0.001). The OS rate of patients with initial pCS was significantly higher than that of patients with second pCS (78.3 vs. 63.0%; P<0.001). Multivariable logistic regression analyses suggested that second pCS predicted higher all-cause mortality (hazard ratio, 1.72; 95% confidence interval, 1.31–2.26, P<0.001) compared with that in patients with initial pCS. Furthermore, there were no differences observed in the treatment benefits between the patients with initial and second pCS. In conclusion, second pCS was more frequently diagnosed in older patients compared with initial pCS. In addition, the prognosis of patients with second pCS was worse than that of patients with initial pCS, and the treatment is essentially the same for initial and second pCS. |
format | Online Article Text |
id | pubmed-6539928 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-65399282019-07-09 Prognosis and treatment differences between initial and second primary chondrosarcoma Mao, Weipu Kong, Minghao Yu, Haiyang Wang, Dongyan Huang, Xin Yao, Xudong Fan, Jie Geng, Jiang Oncol Lett Articles Prognosis and treatment differences between initial and second primary chondrosarcoma (pCS) remain unknown. In the present study, patients with chondrosarcoma diagnosed between January 2004 and December 2015 were identified using the Surveillance Epidemiology and End Results database. Kaplan-Meier curves and log-rank tests were used to assess overall survival (OS) and cancer-specific survival. Univariable and multivariable Cox regression analyses were used to determine factors associated with all-cause mortality and cancer-specific mortality. In total, 1,655 eligible patients were included in the cohort of the present study, of which, 1,455 (87.9%) had initial pCS and 200 (12.1%) had second pCS. Patients with second pCS were more frequently diagnosed in the age range of 61–80 years compared with patients with initial pCS (52.5 vs. 43.1%; P<0.001). The OS rate of patients with initial pCS was significantly higher than that of patients with second pCS (78.3 vs. 63.0%; P<0.001). Multivariable logistic regression analyses suggested that second pCS predicted higher all-cause mortality (hazard ratio, 1.72; 95% confidence interval, 1.31–2.26, P<0.001) compared with that in patients with initial pCS. Furthermore, there were no differences observed in the treatment benefits between the patients with initial and second pCS. In conclusion, second pCS was more frequently diagnosed in older patients compared with initial pCS. In addition, the prognosis of patients with second pCS was worse than that of patients with initial pCS, and the treatment is essentially the same for initial and second pCS. D.A. Spandidos 2019-07 2019-05-07 /pmc/articles/PMC6539928/ /pubmed/31289490 http://dx.doi.org/10.3892/ol.2019.10329 Text en Copyright: © Mao et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Mao, Weipu Kong, Minghao Yu, Haiyang Wang, Dongyan Huang, Xin Yao, Xudong Fan, Jie Geng, Jiang Prognosis and treatment differences between initial and second primary chondrosarcoma |
title | Prognosis and treatment differences between initial and second primary chondrosarcoma |
title_full | Prognosis and treatment differences between initial and second primary chondrosarcoma |
title_fullStr | Prognosis and treatment differences between initial and second primary chondrosarcoma |
title_full_unstemmed | Prognosis and treatment differences between initial and second primary chondrosarcoma |
title_short | Prognosis and treatment differences between initial and second primary chondrosarcoma |
title_sort | prognosis and treatment differences between initial and second primary chondrosarcoma |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6539928/ https://www.ncbi.nlm.nih.gov/pubmed/31289490 http://dx.doi.org/10.3892/ol.2019.10329 |
work_keys_str_mv | AT maoweipu prognosisandtreatmentdifferencesbetweeninitialandsecondprimarychondrosarcoma AT kongminghao prognosisandtreatmentdifferencesbetweeninitialandsecondprimarychondrosarcoma AT yuhaiyang prognosisandtreatmentdifferencesbetweeninitialandsecondprimarychondrosarcoma AT wangdongyan prognosisandtreatmentdifferencesbetweeninitialandsecondprimarychondrosarcoma AT huangxin prognosisandtreatmentdifferencesbetweeninitialandsecondprimarychondrosarcoma AT yaoxudong prognosisandtreatmentdifferencesbetweeninitialandsecondprimarychondrosarcoma AT fanjie prognosisandtreatmentdifferencesbetweeninitialandsecondprimarychondrosarcoma AT gengjiang prognosisandtreatmentdifferencesbetweeninitialandsecondprimarychondrosarcoma |